查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947847

質體DNA生產市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、製程、階段及設備分類

Plasmid DNA Manufacturing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Equipment
出版日期: | 出版商: Global Insight Services | 英文 380 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

質體DNA生產市場預計將從2024年的32億美元成長到2034年的202億美元，複合年成長率約為17.7%。質體DNA生產市場涵蓋用於基因治療、疫苗研發和生物技術研究的質體DNA生產。該市場的成長主要得益於基因工程技術的進步和對個人化醫療日益成長的需求。關鍵趨勢包括大規模生產技術的創新，以確保品質和安全，並符合監管要求。生物製藥研發投入的增加和基因治療方法範圍的擴大也是推動市場成長的因素。

受基因治療和疫苗研發進展的推動，質體DNA生產市場預計將迎來顯著成長。基因治療領域預計將呈現最高成長率，這主要得益於臨床試驗和治療應用的不斷增加。該領域對用於CAR-T細胞療法的高品質質體DNA的需求尤為突出。疫苗研發，特別是針對新興感染疾病，是第二大成長領域，質體DNA在新型疫苗平台中扮演關鍵角色。契約製造組織（CMO）子領域憑藉其可擴展的生產解決方案和法規遵從方面的專業知識，正日益受到關注。研究級質體DNA在學術和臨床研究中仍然至關重要，並保持著穩定的成長。同時，在嚴格的監管要求和對高純度產品的需求推動下，GMP級質體DNA領域正在快速擴張。發酵和純化技術的創新正在提高生產效率，進一步促進市場擴張。策略夥伴關係和聯合研究正在重塑競爭格局，並推動創新和市場滲透。

市場區隔
類型 高拷貝數，低拷貝數
產品 GMP級質體DNA，非GMP級質體DNA
服務 質體DNA純化、質體DNA擴增、品管檢測
科技 發酵技術、鹼溶解法、離子交換層析法
應用 基因療法、DNA疫苗、免疫療法、細胞療法
最終用戶 生物製藥公司、受託研究機構、學術研究機構
過程 上游工程，下游過程
步 臨床前、臨床、商業化
裝置 生物反應器、離心機、層析法系統

質體DNA生產市場正經歷動態的市場佔有率變化，這主要受創新定價策略和新產品快速上市的推動。各公司正利用先進的生物技術方法來強化其產品線，增強競爭優勢。質體。定價仍是關鍵因素，各公司正採用具競爭力的定價模式來擴大市場佔有率。針對尚未滿足的需求推出新產品，進一步強化了這個策略方針。質體DNA生產市場的競爭日益激烈，主要參與者正致力於透過技術創新和策略聯盟來實現差異化。監管的影響，尤其是在北美和歐洲，透過制定嚴格的品質標準，正在重塑競爭格局。這些法規對於確保產品的安全性和有效性至關重要，並影響企業的市場准入和擴大策略。該市場由成熟企業和新興Start-Ups組成，每家公司都在爭奪主導。分析表明，持續創新和遵守法規是保持競爭優勢的關鍵。

主要趨勢和促進因素：

受基因療法和疫苗需求不斷成長的推動，質體DNA生產市場正經歷強勁成長。關鍵趨勢包括生技公司加大研發投入以提高質體DNA生產效率。慢性病和遺傳性疾病的增加進一步推動了市場發展，而質體DNA是創新治療方法開發的關鍵組成部分。生物製程和純化方法的技術進步正在簡化生產流程、降低成本並提高產量。這導致市場參與企業增多，競爭加劇，並刺激了創新。此外，質體DNA在個人化醫療和合成生物學領域的應用不斷擴展，也為市場開闢了新的成長途徑。監管部門的核准和政府對生物技術研究的支持也是關鍵促進因素，進一步推動了市場擴張。新興市場擁有不斷完善的醫療基礎設施和日益成長的先進治療方法需求，蘊藏著許多機會。專注於擴充性和永續性生產流程的公司將更有利於掌握這些機會。在全球對精準醫療日益關注的背景下，在不斷尋求新的治療方案的推動下，質粒DNA生產市場預計將持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 高拷貝數
    • 低拷貝數
  • 市場規模及預測：依產品分類
    • GMP級質體DNA
    • 非GMP級質體DNA
  • 市場規模及預測：依服務分類
    • 質體DNA純化
    • 質體DNA擴增
    • 品管測試
  • 市場規模及預測：依技術分類
    • 發酵技術
    • 鹼溶解法
    • 離子交換層析法
  • 市場規模及預測：依應用領域分類
    • 基因治療
    • DNA疫苗
    • 免疫療法
    • 細胞療法
  • 市場規模及預測：依最終用戶分類
    • 生物製藥公司
    • 合約研究機構
    • 學術研究機構
  • 市場規模及預測：依製程分類
    • 上游工程
    • 下游工藝
  • 市場規模及預測：依疾病階段分類
    • 臨床前階段
    • 臨床
    • 商業的
  • 市場規模及預測：依設備分類
    • 生物反應器
    • 離心機
    • 層析法系統

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Aldevron
  • Cobra Biologics
  • VGXI
  • Gen Script Biotech
  • Plasmid Factory
  • Kaneka Eurogentec
  • Biovian
  • Waisman Biomanufacturing
  • Creative Biogene
  • Nature Technology Corporation
  • Cell and Gene Therapy Catapult
  • Luminous Biosciences
  • Gene Art
  • Biomay
  • Richter-Helm Bio Logics
  • Eurofins Genomics
  • Bio Cina
  • Creative Biolabs
  • Syn Plasmid
  • Bioneer

第9章：關於我們

簡介目錄
Product Code: GIS26480

Plasmid DNA Manufacturing Market is anticipated to expand from $3.2 billion in 2024 to $20.2 billion by 2034, growing at a CAGR of approximately 17.7%. The Plasmid DNA Manufacturing Market encompasses the production of plasmid DNA for applications in gene therapy, vaccine development, and biotechnology research. This market is driven by advancements in genetic engineering and increasing demand for personalized medicine. Key trends include innovations in large-scale production techniques and regulatory compliance to ensure quality and safety. The market's growth is propelled by rising investments in biopharmaceutical R&D and the expanding scope of gene-based therapies.

The Plasmid DNA Manufacturing Market is poised for significant growth, driven by advancements in gene therapy and vaccine development. The gene therapy segment is the top-performing area, propelled by increasing clinical trials and therapeutic applications. Within this segment, the demand for high-quality plasmid DNA for CAR-T cell therapies is particularly noteworthy. Vaccine development, particularly in response to emerging infectious diseases, is the second-highest performing segment, with plasmid DNA playing a crucial role in novel vaccine platforms. The contract manufacturing organizations (CMOs) sub-segment is gaining traction, offering scalable production solutions and expertise in regulatory compliance. Research-grade plasmid DNA remains essential for academic and clinical research, maintaining steady growth. Meanwhile, the GMP-grade plasmid DNA segment is expanding rapidly, driven by stringent regulatory requirements and the need for high-purity products. Innovations in fermentation and purification technologies are enhancing production efficiency, further supporting market expansion. Strategic partnerships and collaborations are increasingly shaping the competitive landscape, fostering innovation and market penetration.

Market Segmentation
TypeHigh Copy Number, Low Copy Number
ProductGMP Grade Plasmid DNA, Non-GMP Grade Plasmid DNA
ServicesPlasmid DNA Purification, Plasmid DNA Amplification, Quality Control Testing
TechnologyFermentation Technology, Alkaline Lysis, Ion Exchange Chromatography
ApplicationGene Therapy, DNA Vaccines, Immunotherapy, Cell Therapy
End UserBiopharmaceutical Companies, Contract Research Organizations, Academic and Research Institutes
ProcessUpstream Processing, Downstream Processing
StagePreclinical, Clinical, Commercial
EquipmentBioreactors, Centrifuges, Chromatography Systems

The Plasmid DNA Manufacturing Market is experiencing dynamic shifts in market share, driven by innovative pricing strategies and an influx of new product launches. Companies are leveraging advanced biotechnological methods to enhance product offerings, thereby increasing their competitive edge. The market is witnessing a surge in demand due to the rising application of plasmid DNA in gene therapy and vaccine development. Pricing remains a critical factor, with firms adopting competitive pricing models to capture a larger share of the market. This strategic approach is further amplified by the introduction of novel products aimed at addressing unmet medical needs. Competition in the Plasmid DNA Manufacturing Market is intensifying, with key players focusing on differentiation through technological advancements and strategic collaborations. Regulatory influences, particularly in North America and Europe, are shaping the competitive landscape by establishing stringent quality standards. These regulations are pivotal in ensuring product safety and efficacy, thereby influencing market entry and expansion strategies. The market is characterized by a blend of established firms and emerging startups, each vying for dominance. Analytical insights reveal that continuous innovation and regulatory compliance are crucial for maintaining competitive advantage.

Geographical Overview:

The Plasmid DNA Manufacturing Market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by advancements in gene therapy and a robust biotechnology sector. The presence of major pharmaceutical companies and research institutions further propels the market's expansion. Europe follows, with strong regulatory frameworks and increasing investments in biotechnology research and development. This region's commitment to innovation and healthcare is fostering a conducive environment for plasmid DNA manufacturing. In Asia Pacific, the market is experiencing rapid growth, spurred by rising healthcare demands and government support for biopharmaceutical advancements. Countries like China and India are emerging as pivotal players due to their expanding biomanufacturing capabilities and cost-effective production. Latin America and the Middle East & Africa present emerging opportunities, with growing investments in biotechnology and a focus on enhancing healthcare infrastructure. These regions are recognizing the potential of plasmid DNA in addressing unmet medical needs and advancing therapeutic solutions.

Global tariffs and geopolitical tensions are profoundly influencing the Plasmid DNA Manufacturing Market, particularly in East Asia. Japan and South Korea are navigating these challenges by enhancing their biotechnological capabilities and reducing reliance on foreign inputs, while China accelerates its domestic production to mitigate export constraints. Taiwan, crucial to the biotech supply chain, is strategically bolstering its resilience amid US-China tensions. The parent market, driven by advancements in gene therapy and personalized medicine, is experiencing robust growth. By 2035, the market is anticipated to flourish through strategic alliances and technological innovation. Meanwhile, Middle East conflicts continue to exert pressure on global supply chains and energy prices, indirectly affecting production costs and timelines in the plasmid DNA sector.

Key Trends and Drivers:

The Plasmid DNA Manufacturing Market is experiencing robust growth driven by the escalating demand for gene therapy and vaccines. A key trend is the increasing investment in research and development by biotechnology firms to enhance plasmid DNA production efficiency. The rise in chronic diseases and genetic disorders is further propelling the market, as plasmid DNA is crucial for developing innovative treatments. Technological advancements in bioprocessing and purification methods are streamlining production processes, reducing costs, and improving yield. This is attracting more players into the market, thereby intensifying competition and fostering innovation. Additionally, the expanding application of plasmid DNA in personalized medicine and synthetic biology is creating new avenues for growth. Regulatory approvals and government support for biotech research are also significant drivers, facilitating market expansion. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and demand for advanced therapies is rising. Companies focusing on scalable and sustainable manufacturing processes are well-positioned to capture these opportunities. As the global focus on precision medicine intensifies, the Plasmid DNA Manufacturing Market is poised for sustained growth, driven by the continuous pursuit of novel therapeutic solutions.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 High Copy Number
    • 4.1.2 Low Copy Number
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 GMP Grade Plasmid DNA
    • 4.2.2 Non-GMP Grade Plasmid DNA
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Plasmid DNA Purification
    • 4.3.2 Plasmid DNA Amplification
    • 4.3.3 Quality Control Testing
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Fermentation Technology
    • 4.4.2 Alkaline Lysis
    • 4.4.3 Ion Exchange Chromatography
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Gene Therapy
    • 4.5.2 DNA Vaccines
    • 4.5.3 Immunotherapy
    • 4.5.4 Cell Therapy
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biopharmaceutical Companies
    • 4.6.2 Contract Research Organizations
    • 4.6.3 Academic and Research Institutes
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical
    • 4.8.3 Commercial
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 Bioreactors
    • 4.9.2 Centrifuges
    • 4.9.3 Chromatography Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Aldevron
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Cobra Biologics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 VGXI
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Gen Script Biotech
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Plasmid Factory
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Kaneka Eurogentec
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Biovian
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Waisman Biomanufacturing
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Creative Biogene
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Nature Technology Corporation
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Cell and Gene Therapy Catapult
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Luminous Biosciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Gene Art
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Biomay
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Richter- Helm Bio Logics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Eurofins Genomics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bio Cina
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Creative Biolabs
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Syn Plasmid
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bioneer
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us